

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF: David A. Griffith :

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned :

FILING DATE: To Be Assigned

:Group Art Unit: To Be Assigned

TITLE: Cannabinoid Receptor Ligands and Uses Thereof :  
-----

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: January 21, 2004

Respectfully submitted,

Arlene K. Musser

Arlene K. Musser  
Attorney for Applicant(s)  
Reg. No. 37,895

Pfizer Inc.  
Patent Department, Box 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 715-0871

EXPRESS MAIL NO. 50271824831US

INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A		SERIAL NO. To Be		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE Herewith		GROUP To Be		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 3,865,824	02/11/75	Kobe, et al.			
	US 3,910,907	10/07/75	O'Brien, et al.			
	US 3,995,039	11/30/76	Rooney, et al.			
	US 4,183,930	01/15/80	Cohen			
	US 4,734,414	03/29/88	Kim			
	US 4,767,858	08/30/88	Kim			
	US 4,824,834	04/25/89	Fujii, et al.			
	US 4,992,442	02/12/91	Tsujitani, et al.			
	US 5,055,479	10/08/91	Takiguchi, et al.			
	US 5,086,057	02/04/92	Takiguchi, et al.			
	US 5,137,887	08/11/92	Hashimoto, et al.			
	US 5,246,932	09/21/93	Caulkett, et al.			
	US 5,270,311	12/14/93	Caulkett, et al.			
	US 5,290,776	03/01/94	Caulkett, et al.			
	US 5,356,894	10/18/94	Rodney, et al.			
	US 5,380,714	01/10/98	Jones, et al.			
	US 5,420,128	05/30/95	Kiyokawa, et al.			
	US 5,571,813	11/05/96	Ruhter, et al.			
	US 5,602,136	02/11/97	Ruhter, et al.			
	US 5,602,137	02/11/97	Ruhter, et al.			
	US 6,060,478	05/09/00	Gilligan, et al.			
	US 6,124,289	09/26/00	He, et al.			

EXPRESS MAIL NO. 2V27182483105

INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)		ATTY. DOCKET NO. PC25512A		SERIAL NO. To Be Assigned		
		APPLICANT DAVID A. GRIFFITH				
		FILING DATE Herewith		GROUP To Be Assigned		
	US 6,136,809	10/24/00	Gilligan, et al.			
	US 6,191,131 B1	02/20/01	He, et al.			
	US 6,194,410 B1	02/27/01	Bos, et al.			
	US 6,313,124 B1	11/06/01	He, et al.			
	US 6,358,950 B1	03/19/02	He, et al.			
	US 6,372,743 B1	04/16/02	Darrow, et al.			
	US 6,476,038 B1	11/05/02	Darrow, et al.			
	US 6,509,338 B1	01/21/03	Olson, et al.			
	US 2003/0008885 A1	01/09/03	He, et al.			
	US 2003/0125330 A1	07/03/03	Gilligan			
<b>FOREIGN PATENT DOCUMENTS</b>						
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	EP 269 859 B2	10/18/95	Europe			
	WO 01/54695 A1	08/02/03	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	Sato, Yasunobu, et al., "Studies on Cardiovascular Agents. 6. Synthesis and Coronary Vasodilating and Antihypertensive Activities of 1,2,4-Triazolo[1,5-a]pyrimidines Fused to Heterocyclic Systems," <u>J. Med. Chem.</u> , <b>23</b> , 927-937 (1980).					
	Senga, Keitaro, et al., "Synthesis and Antischistosomal Activity of Certain Pyrazolo[1,5-a]pyrimidines," <u>J. Med Chem.</u> , <b>24</b> , 610-613 (1981).					
	Senga, Keitaro, et al., "Synthesis and Enzymic Activity of Various Substituted Pyrazolo[1,5-a]-1,3,5-triazines as Adenosine Cyclic 3',5'-Phosphate Phosphodiesterase Inhibitors," <u>J Med Chem.</u> , <b>25</b> , 243-249 (1982).					
	He, Liqi, et al., "4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine: A Potent, Orally bioavailable CRF3 Receptor Antagonist," <u>J Med Chem.</u> , <b>43</b> , 449-456 (2000).					
	Almansa, Carmen, et al., "Synthesis and SAR of a New Series of COX-2 Selective Inhibitors: Pyrazolo[1,5-a]pyrimidines," <u>J Med Chem.</u> , <b>44</b> , 350-361 (2001).					
EXAMINER		DATE CONSIDERED				